Diligence memo · auto-generated · as of July 2, 2026
O2 Medtech Inc
O2 Medtech Inc looks over-valued against its niche peers and is dormant on financing cadence.
Businessfiled
O2 Medtech Inc operates in Biotechnology, based in LOS ALTOS.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
O2 Medtech Inc has raised $7.1M in disclosed capital across 3 recorded rounds, aggregated from public filings. Its latest round is modeled as Seed (a $1.0M–$4.0M round).
Largest single filing: $3.6M on 2011-09-30.
Most recent recorded round closed around 2011-09-30.
Valuation (modeled)modeled
Provath models O2 Medtech Inc at approximately $160M (range $2.6M–$1.3B). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Over-valued. Modeled value is 1.85× the median modeled value of Seed Biotechnology companies in 2010–2012 (151 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Historic cadence: a new round about every 8 months.
Last raise 14.8 yr ago; this sector typically re-raises about every 14 months.
Silent for over 3× the sector's normal cadence.
The last round stepped up 2.4× from the prior — scaling.
Comparablesmixed
Capital scale ranks ahead of 50% of Biotechnology peers (4293 compared).
Modeled value ranks above 68% of those peers.
Closest niche peers: Denali Medical II, Inc., Signum Biosciences, Inc., Health Elements, LLC, Nkt Therapeutics Inc, Surface Logix Inc.
Peoplefiled
7 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
Modeled above niche peers — valuation risk on entry.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.